Product Description
Doxepin is used to treat anxiety or depression. It is also used to treat insomnia (trouble with sleeping). Doxepin is a tricyclic antidepressant (TCA). It works on the central nervous system (CNS) to increase levels of certain chemicals in the brain. This medicine is available only with your doctor's prescription.
Mechanisms of Action: SNR Inhibitor, H1 Antagonist, MR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Canada | Chile | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Israel | Italy | Korea | Lebanon | New Zealand | Norway | Pakistan | Poland | Portugal | Romania | Slovenia | South Africa | Spain | Sri Lanka | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Currax Pharmaceuticals
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Insomnia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20250406 |
CTR20250406 | P1 |
Completed |
Insomnia |
2025-01-23 |
2025-06-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |